Investment House LLC Sells 575 Shares of Pfizer Inc. (NYSE:PFE)

Investment House LLC cut its holdings in shares of Pfizer Inc. (NYSE:PFE) by 2.2% in the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 25,305 shares of the biopharmaceutical company’s stock after selling 575 shares during the quarter. Investment House LLC’s holdings in Pfizer were worth $708,000 as of its most recent SEC filing.

Other hedge funds also recently modified their holdings of the company. Olistico Wealth LLC acquired a new position in Pfizer in the 2nd quarter valued at approximately $25,000. Creekmur Asset Management LLC bought a new position in Pfizer in the fourth quarter worth $32,000. Trivant Custom Portfolio Group LLC boosted its stake in Pfizer by 100.0% during the first quarter. Trivant Custom Portfolio Group LLC now owns 1,200 shares of the biopharmaceutical company’s stock worth $33,000 after buying an additional 600 shares in the last quarter. Tennessee Valley Asset Management Partners bought a new stake in Pfizer in the 4th quarter valued at $36,000. Finally, DiNuzzo Private Wealth Inc. acquired a new position in shares of Pfizer in the 4th quarter valued at $37,000. 68.36% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

PFE has been the topic of a number of analyst reports. Wells Fargo & Company upped their target price on shares of Pfizer from $28.00 to $30.00 and gave the company an “equal weight” rating in a research note on Wednesday, July 31st. StockNews.com raised Pfizer from a “hold” rating to a “buy” rating in a report on Thursday, August 1st. BMO Capital Markets reaffirmed an “outperform” rating and issued a $36.00 price target (up previously from $33.00) on shares of Pfizer in a research note on Thursday, May 2nd. Cantor Fitzgerald reiterated an “overweight” rating and set a $45.00 price objective on shares of Pfizer in a research note on Monday. Finally, Daiwa America raised shares of Pfizer from a “moderate buy” rating to a “strong-buy” rating in a report on Wednesday, August 7th. Eight analysts have rated the stock with a hold rating, seven have given a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat.com, Pfizer has a consensus rating of “Moderate Buy” and an average target price of $34.54.

Pfizer Stock Performance

Shares of Pfizer stock traded up $0.13 during trading on Wednesday, hitting $29.03. 16,580,738 shares of the stock were exchanged, compared to its average volume of 39,231,121. Pfizer Inc. has a 1-year low of $25.20 and a 1-year high of $37.15. The stock has a market capitalization of $164.50 billion, a price-to-earnings ratio of -483.67, a price-to-earnings-growth ratio of 1.00 and a beta of 0.69. The company has a fifty day moving average price of $28.78 and a 200-day moving average price of $27.93. The company has a current ratio of 0.86, a quick ratio of 0.60 and a debt-to-equity ratio of 0.65.

Pfizer (NYSE:PFE) last released its quarterly earnings data on Tuesday, July 30th. The biopharmaceutical company reported $0.60 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.46 by $0.14. The firm had revenue of $13.28 billion for the quarter, compared to analyst estimates of $12.96 billion. Pfizer had a positive return on equity of 8.42% and a negative net margin of 4.66%. The business’s revenue for the quarter was up 2.1% compared to the same quarter last year. During the same quarter in the prior year, the company earned $0.67 earnings per share. As a group, equities analysts predict that Pfizer Inc. will post 2.68 EPS for the current fiscal year.

Pfizer Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 3rd. Stockholders of record on Friday, July 26th will be given a $0.42 dividend. This represents a $1.68 annualized dividend and a dividend yield of 5.79%. The ex-dividend date of this dividend is Friday, July 26th. Pfizer’s payout ratio is presently -2,800.00%.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.